🇺🇸 FDA
Drug

pimavanserin tartrate

Brand: NUPLAZID

approved

Quick answer

pimavanserin tartrate (NUPLAZID), is a pharmaceutical active ingredient, associated with ACADIA PHARMACEUTICALS INC, with approved status in the US.

Key facts

INN
pimavanserin tartrate
Brand
NUPLAZID
Route
ORAL
Formulation
CAPSULE
Originator
ACADIA PHARMACEUTICALS INC

Related patents

patent

US 11464768

Pimavanserin alone or in combination for use in the treatment of Alzheimer's dis

Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11452721

Formulations of pimavanserin

Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11191757

Combination of pimavanserin and cytochrome P450 modulators

Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11135211

Pimavanserin for treating impulse control disorder

Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10953000

Combination of pimavanserin and cytochrome P450 modulators

Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10849891

Formulations of pimavanserin

Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10646480

Formulations of pimavanserin

Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10517860

Combination of pimavanserin and cytochrome P450 modulators

Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

Frequently asked questions

What is pimavanserin tartrate?

pimavanserin tartrate (NUPLAZID), is a pharmaceutical active ingredient, associated with ACADIA PHARMACEUTICALS INC, with approved status in the US.

What is the brand name for pimavanserin tartrate?

NUPLAZID is a marketed brand name for pimavanserin tartrate. Check FDA Drugs@FDA for the current US label holder.